Moreover, high levels of serum VEGF in patients with advanced melanoma was associated with poorer overall survival when treated with ipilimumab (anti-CTLA4 antibody) and also predicted lack of response to high-dose IL-2 therapy [30, 31]. The gene discussed is CTLA4; the disease is melanoma.